Psoriasis Clinical Trials
Currently Enrolling
- Regeneron Protocol R668-AD-1762: A prospective observational study of adult patients receiving Dupixent® for atopic dermatitis. For patients 12 years and older. | Learn More » | Sign Up for This Study »
- Corrona Protocol PSO-500: A Phase 4 study of the comparative safety of approved psoriasis therapies in a national cohort of psoriasis subjects treated by dermatologists. Compares systemic psoriasis therapies that are available for prescription. | Learn More » | Sign Up for This Study »
- Abbvie protocol M19-164: A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Have a Suboptimal Response to Secukinumab or Ixekizumab and Are Switched to Risankizumab. | Learn More » | Sign Up for This Study »
- Corrona Psoriasis Registry: Any adult patient who started a biologic therapy in the past year, or is being prescribed a biologic therapy, is eligible! Patients come to the Rockville office every 6 months for 8 years will receive a $25 gift card. | Learn More » | Sign Up for This Study »
- Skyrizi: Adult patients who have failed Cosentyx or Taltz could be eligible to participate in this open-label study investigating Skyrizi. 1 year of treatment at no cost to patients! | Learn More » | Sign Up for This Study »
Active / Not Enrolling
- ESPRIT Chronic Plaque Psoriasis Registry: A 10-year registry of patients taking HUMIRA® for Psoriasis. Patients who volunteer to participate will be asked to provide information about their medical history and experiences with HUMIRA®. No registry-specific testing will be performed. Patients will be asked to provide data on their experiences with HUMIRA® approximately every 6 months, or as determined by the study doctor. No drug will be provided as a result of participation in the registry. All treatment decisions are independent of participation in the registry. | Learn More » | No Longer Enrolling
- Celgene Protocol 826652: A Phase 4, open-label study of the effects of apremilast on vascular inflammation and cardiometabolic function in psoriasis. For adult patients with moderate to severe plaque psoriasis. | Learn More » | No Longer Enrolling
- Lilly Protocol I6T-MC-AMAH: A Phase 3, multicenter, long-term extension to evaluate the long-term safety and maintenance of treatment effect of LY3074828 (il-23 inhibitor) in patients with moderate-to-severe plaque psoriasis who have previously completed participation in I6T-MC-AMAH. | Learn More » | No Longer Enrolling
